MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gresh, N.
Right arrow Articles by Pullman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gresh, N.
Right arrow Articles by Pullman, B.

A theoretical study of the nonintercalative binding of berenil and stilbamidine to double-stranded (dA-dT)n oligomers

N Gresh and B Pullman

The nonintercalative binding of two diarylamidines , berenil and stilbamidine , to the minor groove of double-stranded (dA-dT)n oligomers in the B-DNA conformation was investigated by performing theoretical computations of their intermolecular interaction energies with the groove. The method consists of an additive procedure developed previously in this laboratory using empirical formulae based on ab initio computations. The objective was to assess the extent to which the particular structure of each diarylamidine bears on its binding mode and affinity to the minor groove. The results show that the intrinsically preferred configurations of the two compounds are markedly different. Owing to its slightly curved shape, berenil interacts with the groove predominantly through its concave side, the binding occurring principally with sites (O2, O1) belonging to two thymidines on the opposite strands. The binding of stilbamidine involves a more limited number of hydrogen-bonding interactions, although an appreciably large number of interatomic distances between its hydrogens and sites on the groove (O2, N3, O1) falls in the range 2.7-3.1 A. Each side of stilbamidine with respect to its long axis faces a distinct strand of DNA. The importance of the electrostatic contribution of the binding energy of the two diarylamidines is underlined. Preferential binding of berenil rather than of stilbamidine occurs only at the level of a complete helical turn of phosphates in (dA-dT)n. The energy difference increases significantly upon further buildup of phosphates. These results can be interpreted in terms of the molecular electrostatic potential in the grooves.

Volume 25, Issue 3, pp. 452-458, 05/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Lansiaux, F. Tanious, Z. Mishal, L. Dassonneville, A. Kumar, C. E. Stephens, Q. Hu, W. D. Wilson, D. W. Boykin, and C. Bailly
Distribution of Furamidine Analogues in Tumor Cells: Targeting of the Nucleus or Mitochondria Depending on the Amidine Substitution
Cancer Res., December 15, 2002; 62(24): 7219 - 7229.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
J. C. Stockert, C. I. Trigoso, T. Cuellar, J. L. Bella, and J. A. Lisanti
A New Fluorescence Reaction in DNA Cytochemistry: Microscopic and Spectroscopic Studies on the Aromatic Diamidino Compound M&B 938
J. Histochem. Cytochem., January 1, 1997; 45(1): 97 - 106.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. N. Kaytor, J. L. Zhu, C.-I Pao, and L. S. Phillips
Insulin-responsive Nuclear Proteins Facilitate Sp1 Interactions with the Insulin-like Growth Factor-I Gene
J. Biol. Chem., September 28, 2001; 276(40): 36896 - 36901.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics